Protagonist Therapeutics Inc
NASDAQ:PTGX 4:00:00 PM EDT
| Market Cap (Intraday) | 3.61B |
| Current PE | 69.40 |
| Forward PE | N/A |
| 2yr Forward PE | 367.88 |
| 10-Day MA | $58.56 |
| 50-Day MA | $55.70 |
| 200-Day MA | $47.28 |
Protagonist Therapeutics Inc Stock, NASDAQ:PTGX
7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
United States of America
Phone: +1.510.474.0170
Number of Employees: 126
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.